Journal Title:Cancer Biology & Therapy
Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.
癌症是导致死亡的第二大原因,是由 100 多种疾病组成的异质组。癌症的特征是细胞和基质增殖紊乱和失调,伴随着细胞死亡减少,能够在营养和生长因子剥夺、缺氧和细胞间接触丧失的压力下生存。在分子水平上,癌症是一种遗传疾病,是由于体细胞中突变随时间累积而发展起来的。表型包括基因组不稳定性和允许加速遗传变化的染色体非整倍性。任何细胞的恶性转化和肿瘤进展都需要永生化、检查点控制的丧失、生长失调和存活。大量的细胞和分子遗传变化以及伴随肿瘤发展和进展的宿主-肿瘤相互作用已经被了解。分子肿瘤学领域的目标是利用这些知识来了解癌症发病机制和药物作用,以及开发更有效的癌症诊断和治疗策略。这包括预防策略以及治疗转移的方法。随着人类基因组序列以及基因组和蛋白质组学方法的可用性,大量工具和资源正在产生更多信息。挑战将是从信息中获得生物学意义,开发适当的模型和假设,并为临床医生和患者的利益翻译信息。癌症生物学与治疗旨在发表关于癌症分子基础的原创研究,包括与诊断或治疗具有转化相关性的文章。我们将包括涵盖期刊广泛范围的及时评论。该杂志还将发表评论文章和感兴趣的会议报告。目标是通过使用传统和电子格式及时发布重要结果来促进信息交流和快速交流。期刊和杰出的编辑委员会将努力在所有活动中保持最高标准,以产生宝贵的资源。
Cancer Biology & Therapy创刊于2002年,由TAYLOR & FRANCIS INC出版商出版,收稿方向涵盖医学 - 肿瘤学全领域,此刊是中等级别的SCI期刊,所以过审相对来讲不是特别难,但是该刊专业认可度不错,仍然是一本值得选择的SCI期刊 。平均审稿速度约2.3月,影响因子指数3.659,该期刊近期没有被列入国际期刊预警名单,广大学者值得一试。
大类学科 | 分区 | 小类学科 | 分区 | Top期刊 | 综述期刊 |
医学 | 3区 | ONCOLOGY 肿瘤学 | 4区 | 是 | 是 |
名词解释:
中科院分区也叫中科院JCR分区,基础版分为13个大类学科,然后按照各类期刊影响因子分别将每个类别分为四个区,影响因子5%为1区,6%-20%为2区,21%-50%为3区,其余为4区。
WOS分区等级 | JCR所属学科 | 分区 |
Q2 | ONCOLOGY | Q2 |
名词解释:
WOS即Web of Science,是全球获取学术信息的重要数据库,Web of Science包括自然科学、社会科学、艺术与人文领域的信息,来自全世界近9,000种最负盛名的高影响力研究期刊及12,000多种学术会议多学科内容。给期刊分区时会按照某一个学科领域划分,根据这一学科所有按照影响因子数值降序排名,然后平均分成4等份,期刊影响因子值高的就会在高分区中,最后的划分结果分别是Q1,Q2,Q3,Q4,Q1代表质量最高。
CiteScore | SJR | SNIP | CiteScore排名 | ||||||||||||||||||||
9.80 | 0.996 | 0.866 |
|
名词解释:
CiteScore:衡量期刊所发表文献的平均受引用次数。
SJR:SCImago 期刊等级衡量经过加权后的期刊受引用次数。引用次数的加权值由施引期刊的学科领域和声望 (SJR) 决定。
SNIP:每篇文章中来源出版物的标准化影响将实际受引用情况对照期刊所属学科领域中预期的受引用情况进行衡量。
是否OA开放访问: | h-index: | 年文章数: |
未开放 | 101 | 145 |
Gold OA文章占比: | 2021-2022最新影响因子(数据来源于搜索引擎): | 开源占比(OA被引用占比): |
42.41% | 3.6 | 0.20... |
研究类文章占比:文章 ÷(文章 + 综述) | 期刊收录: | 中科院《国际期刊预警名单(试行)》名单: |
90.16% | SCI、SCIE | 否 |
历年IF值(影响因子):
历年引文指标和发文量:
历年中科院JCR大类分区数据:
历年自引数据:
2019-2021国家/地区发文量统计:
国家/地区 | 数量 |
CHINA MAINLAND | 291 |
USA | 133 |
Italy | 13 |
India | 10 |
Japan | 9 |
England | 8 |
GERMANY (FED REP GER) | 6 |
South Korea | 6 |
Brazil | 4 |
Poland | 4 |
2019-2021机构发文量统计:
机构 | 数量 |
ZHENGZHOU UNIVERSITY | 21 |
SHANGHAI JIAO TONG UNIVERSITY | 14 |
SHANDONG UNIVERSITY | 13 |
TIANJIN MEDICAL UNIVERSITY | 13 |
VIRGINIA COMMONWEALTH UNIVERSITY | 13 |
CHINA MEDICAL UNIVERSITY | 11 |
CHINESE ACADEMY OF MEDICAL SCIEN... | 11 |
PENNSYLVANIA COMMONWEALTH SYSTEM... | 11 |
HUAZHONG UNIVERSITY OF SCIENCE &... | 10 |
NANJING MEDICAL UNIVERSITY | 10 |
近年引用统计:
期刊名称 | 数量 |
CANCER RES | 166 |
NATURE | 136 |
CLIN CANCER RES | 130 |
PLOS ONE | 124 |
ONCOGENE | 115 |
J CLIN ONCOL | 96 |
NEW ENGL J MED | 94 |
CELL | 89 |
J BIOL CHEM | 86 |
P NATL ACAD SCI USA | 86 |
近年被引用统计:
期刊名称 | 数量 |
CANCERS | 284 |
INT J MOL SCI | 196 |
SCI REP-UK | 143 |
FRONT ONCOL | 131 |
J CELL PHYSIOL | 128 |
J CELL BIOCHEM | 118 |
ONCOL LETT | 110 |
ONCOTARGETS THER | 101 |
CELLS-BASEL | 87 |
BMC CANCER | 65 |
近年文章引用统计:
文章名称 | 数量 |
Circular RNA ciRS-7 triggers the... | 42 |
Life and death of circulating ce... | 33 |
LncRNA PTCSC3 affects drug resis... | 23 |
LncRNA NEAT1/let-7a-5p axis regu... | 22 |
Emerging roles of circRNA_NEK6 t... | 21 |
Breast cancer lung metastasis: M... | 21 |
M2-like tumor-associated macroph... | 19 |
Long non-coding RNA HOTAIR promo... | 19 |
LncRNA DUXAP10 modulates cell pr... | 19 |
A regulatory circuit of circ-MTO... | 18 |
同类学科的其他优质期刊 | 影响因子 | 中科院分区 |
Journal Of Clinical Microbiology | 5.897 | 2区 |
Science And Medicine In Football | 4区 | |
Acta Bioethica | 0.153 | 4区 |
Alcoholism-clinical And Experimental Research | 3.035 | 3区 |
Orthodontics & Craniofacial Research | 1.455 | 3区 |
Israel Journal Of Psychiatry And Related Sciences | 0.600 | 4区 |
Australian And New Zealand Journal Of Public Health | 2.079 | 3区 |
Cytokine & Growth Factor Reviews | 5.982 | 2区 |
Sleep Medicine | 3.038 | 2区 |
Brain Tumor Pathology | 2.348 | 3区 |
本站主要从事期刊咨询服务,不是任何杂志官网,不涉及任何出版事务、本站仅提供有限咨询服务,需要用户自己向出版商投搞且没有绿色通道,是否录用一切以出版商通知为准,本站提供的期刊信息均来源于国家新闻出版总署及网络,仅供参考,提及的第三方名称或商标,其知识产权均属于相应的出版商或期刊,本站与上述机构无从属关系,所有引用均出于解释服务内容的考量,符合商标法规范,本页信息均由法务团队进行把关,若期刊信息有任何问题,请联系我们,我们会认真核实处理。若用户需要出版服务,请联系出版商!
发表直通车,欢迎来到发表直通车
鲁ICP备2024070538号-2
鲁公网安备37152102000140